Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients

Clinical trial NCT02175446 · UNKNOWN

Trial details

NCT number: NCT02175446
Sponsor: Consorzio Oncotech
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Start date: 2014-09-01
Primary completion: 2016-12-01
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.